Undergraduate Research Conference

42nd Annual Undergraduate Research Conference
Friday, April 22, 2016
Undergraduate Research Conference The College takes seriously the role of research in the liberal arts education of undergraduates. Students regularly benefit from direct contact with our research faculty and are empowered and encouraged to conduct their own inquiries. All undergraduates at the University are invited to participate in and present their research at the College’s 42nd annual Undergraduate Research Conference on Friday, April 22, 2016. Projects showcasing undergraduate work in the Natural Sciences, Social Sciences and Humanities are welcome. The work may have been done in connection with a course or as independent or supervised study. URC application deadline: Friday, March 25, 2016

Click here to download a copy of the April 24th, 2015 Conference Program

Congratulations to the 2015 Undergraduate Research Winners!

In order to help participants prepare for the Conference, we will be hosting a series of presentation workshops, 2 for students doing panel presentations and 2 for students doing poster presentations.

These interactive workshops will focus on both the theoretical and practical aspects of communicating research.  Faculty from NYU's Writing in the Disciplines program will facilitate these sessions and fellow undergraduates with experience presenting at conferences will also be on hand to answer questions and provide insights from their own experience.  Students attending the sessions are strongly encouraged to bring current drafts of their presentation to receive critique and guidance from fellow students and workshop facilitators.

  • The dates and times for these workshops will be announced in spring 2016.


2015 Conference Preview

cindytsui.jpg Cindy Tsui (CAS ’15) majoring in Computer Science, Pre-Med

Long-Term Durability and Dose Escalation Patterns in Infliximab Therapy for Psoriasis

Psoriasis is a chronic, inflammatory skin disease affecting 3% of the population. The prevailing reason for discontinuation of infliximab treatment for psoriasis is loss of clinical response, requiring dose intensification to optimize the treatment regimen. Furthermore, concomitant immunosuppressive medications, e.g. methotrexate, theoretically extend infliximab durability. Our research shows infliximab dose escalation to be well tolerated in our patient cohort and confirms that concurrent methotrexate is associated with significantly improved maintenance of clinical response. Our experience with intensified infliximab regimens supports the efficacy and safety of dose escalation in treating psoriasis.



All Undergraduate Research Conference presenters are strongly encouraged to attend a workshop entitled "Designing and Delivering Dynamic Presentations."

Click here for slides from the 2014 workshop, "Designing and Delivering Dynamic Presentations."